# Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT07086469** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 69 (estimated)

## Conditions studied

- Toripalimab
- Surufatinib
- Neoadjuvant Immunochemotherapy
- Chemoradiotherapy
- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant immunochemotherapy
- **DRUG:** Surufatinib Administration
- **DRUG:** Concurrent Chemotherapy
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT07086469
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2029-07-19
- **Final completion:** 2029-07-19
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07086469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07086469, "Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07086469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*